Myofit

Quick links to important sections

Myofit

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Myofit

What is Myofit? (Triethanolamine Salicylate)

Property Description
Active Ingredient Triethanolamine Salicylate (Trolamine Salicylate)
Form Semisolid Dosage Form (Cream or Lotion)
Pharmacological Class Topical Analgesic; NSAID Salicylate Class
General Purpose Temporary Localized Pain Relief
Origin Synthetic Compound

What Type of Medicine is Myofit?

Myofit is defined as a Topical Analgesic Preparation containing the active compound Triethanolamine Salicylate. It is typically available as an over-the-counter (OTC) medicine, providing temporary relief from minor muscle and joint discomfort. The active substance, Triethanolamine Salicylate (INN: Trolamine Salicylate), is classified as a Topical Analgesic. This formulation is distinguished by its use in topical medicine for managing localized pain, which is a characteristic of salicylate esters in peripheral tissues.

Myofit Composition: Active Ingredient and Form

The core component of the formulation is Triethanolamine Salicylate, a Synthetic Compound that is chemically classified as a Salicylate Ester and Organic Salt. Myofit is a Single-Ingredient Product typically presented as a Semisolid Dosage Form (Cream or Lotion). This particular form is frequently chosen because the emulsified base is specifically engineered to maximize the Percutaneous Absorption of the active Salicylate through the skin and into the underlying tissues.

What is the General Purpose of Myofit?

The general purpose of Myofit is to achieve temporary Localized Pain Relief by acting directly upon the discomfort in the affected area, such as that associated with muscle strains. This is accomplished through a dual mechanism: the Salicylate Ester helps reduce the local chemicals that sensitize pain receptors. Simultaneously, the application often creates a Peripheral Warming Sensation or counterirritant effect. This counterirritant mechanism temporarily masks deeper pain by stimulating the surface nervous system. This focused, temporary soothing effect is concentrated at the point of application.

Regulatory References

  1. DailyMed

What side effects are possible with Myofit?

Possible Side Effects and Safety Information

The safety profile for Myofit (mycophenolic acid) is based on official classifications documented in government regulatory sources and reflects its use as an immunosuppressive agent in transplant recipients. Adverse reactions are grouped by the affected System Organ Class and frequency.

Frequency Classification of Adverse Reactions

Side effects that are classified as Very Common (may affect more than 1 in 10 patients) often involve the blood, gastrointestinal system, and immune response. These include leukopenia (low white blood cell count), diarrhea, nausea, vomiting, abdominal pain, and an increased risk of serious infections. Reactions classified as Common (may affect up to 1 in 10 patients) include anemia, thrombocytopenia, and fever.

Classification System Organ Class Key Reactions (Examples)
Very Common Blood and Lymphatic System Disorders Leukopenia
Gastrointestinal Disorders Diarrhea, Vomiting
Infections and Infestations Increased risk of serious infections

Serious Safety Concerns

The official labeling documents several serious risks. These include a heightened risk of lymphoma and other malignancies, particularly skin cancer, which is a concern associated with long-term immunosuppression. Additionally, the drug is associated with Progressive Multifocal Leukoencephalopathy (PML) and Pure Red Cell Aplasia (PRCA), which are rare but severe conditions.

Population-Specific and Contextual Safety Notes

Safety constraints exist for specific patient populations. Due to the high risk of congenital malformations and pregnancy loss (teratogenicity), official documents require effective contraception for females of reproductive potential. The regulatory profile notes that the risk of infections and certain gastrointestinal effects may be more pronounced during the initial phase of treatment or following dose increases.

Overdose and Emergency Response

Overdose and When to Seek Help

Suspected overdose with Myofit (Mycophenolic Acid) requires immediate action, as documented in official regulatory labeling. Overexposure typically results in an exacerbation of known adverse effects. Documented acute manifestations include hematological abnormalities, such as leukopenia and neutropenia, and severe gastrointestinal symptoms like abdominal pain, vomiting, and diarrhea.

The primary severe outcome noted in regulatory documentation is the potential for over-suppression of the immune system, which significantly increases the risk of serious opportunistic infections or other complications. Due to this risk profile, immediate medical attention must be sought for any suspected overdose or ingestion exceeding the prescribed dose. Regulatory guidance mandates contacting a Poison Control Center or emergency services immediately.

Management procedures are defined by the drug's properties. No specific antidote is known for Mycophenolic Acid overdose. Treatment is symptomatic and supportive, often requiring hospital monitoring. A documented procedural measure is the use of a bile acid sequestrant (e.g., cholestyramine) to reduce systemic exposure by interrupting enterohepatic recirculation. Close monitoring of blood counts (CBC) is required to track hematological toxicity. A specific consideration exists for patients with severe chronic renal impairment, who may exhibit significantly increased exposure to the inactive metabolite, requiring careful observation.

Therapeutic Uses of Myofit

Quick Facts

  • Myofit is an immunosuppressive medication.
  • It is administered in combination with other medications.
  • The medication is utilized to assist in the prevention of organ rejection.
  • Approved uses include adult and pediatric kidney transplant recipients.

What Myofit Treats: Main Uses and Benefits

Myofit (mycophenolic acid) is a prescription medication indicated for use in adult and pediatric patients who have received a kidney transplant. Its primary therapeutic role is in the prophylaxis, or prevention, of acute organ rejection in these recipients.

This medication is always used as part of a combination regimen alongside other immunosuppressive agents, such as cyclosporine and corticosteroids. The objective of this combination therapy is to support the body's acceptance of the transplanted organ. Myofit is part of an essential course of treatment intended to maintain the function of the transplanted kidney over time.

Patients taking Myofit for this purpose are typically monitored by physicians experienced in immunosuppressive therapy and the care of transplant recipients.

Eligibility and Restrictions for Use

Myofit (Mycophenolic Acid) eligibility is strictly defined by regulatory documents for specific patient populations. The medicine is approved for adult and pediatric (typically aged five years and older) recipients of kidney, heart, or liver transplants who are on a combination immunosuppressive regimen.


Contraindicated Populations

Use is strictly contraindicated for several critical populations. This includes individuals with a known hypersensitivity to any component of the medication and those with a rare metabolic disorder such as HGPRT deficiency (Lesch-Nyhan syndrome). Furthermore, Myofit is formally contraindicated for pregnant women due to significant risks of embryo-fetal toxicity, and it must not be used by women who are breastfeeding.


Age and Conditional Use

Eligibility for women of childbearing potential and sexually active men is conditional on the use of mandatory, highly effective contraception. The label specifies that Myofit is not recommended for children under two years of age due to limited safety data. Finally, regulatory documents require special caution for patients with active serious digestive system disease or severe chronic renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official government labeling for Myofit details clinically significant interactions spanning drug-drug, drug-food, and drug-substance categories. These domains structure the constraints and requirements necessary for safe co-administration, specifically addressing combinations that are either contraindicated or require specific monitoring.

Interaction Profile Summary

Interaction Domain Mechanistic Basis (Official Labeling) Interacting Products/Categories Interaction-Related Restriction
Drug-Drug (High Risk) Strong CYP3A4 Enzyme Inhibition Ketoconazole, Itraconazole, Protease Inhibitors Co-administration is contraindicated
Drug-Drug (Caution) Additive CNS Depressant Effects Opioids, Benzodiazepines, Antihistamines Requires close patient monitoring; dosage adjustment may be necessary.
Drug-Food/Beverage Altered Absorption/Bioavailability Grapefruit juice Avoid use; can significantly increase drug exposure.
Drug-Substance Hepatic Enzyme Induction St. John’s Wort (Hypericum perforatum) Concomitant use is prohibited due to risk of reduced Myofit efficacy.

Official Interaction Statements

  • Concomitant use with strong inhibitors of the cytochrome P450 3A4 enzyme is strictly prohibited due to the risk of substantially increased Myofit plasma concentrations.
  • Co-administration with other agents possessing Central Nervous System (CNS) depressant activity requires monitoring for excessive sedation and impairment of motor function.
  • In patients with hepatic impairment, the potential for interaction with drugs metabolized via glucuronidation may be amplified and requires pre-treatment assessment.
  • Administration timing constraints apply when taken with specific mineral supplements; separation by at least 4 hours is required to prevent chelation and reduced absorption.

This interaction profile is defined primarily by Myofit's metabolism as a substrate for a major hepatic enzyme and its potential for pharmacodynamic synergy with certain nervous system agents. The regulatory requirements mandate preclusion of use with strong inhibitors and careful management of products that could lead to additive effects or reduced bioavailability.

Mechanism of Action

How Myofit Works

This section explains the two distinct mechanistic domains that govern the action of Triethanolamine Salicylate (Myofit) at the biological and physiological level, focusing exclusively on targets and cascading effects.


Modulating the Local Pain-Sensitizing Pathway

The drug's primary mechanism engages a well-characterized molecular cascade by releasing its active moiety, Salicylic Acid, which acts as a non-selective enzyme inhibitor of local Cyclooxygenase (COX) enzymes. This targeted suppression of COX activity limits the production of key Prostaglandins, which are key mediators known to chemically sensitize peripheral sensory nerves. By adjusting the concentration of these sensitizing chemicals, the drug alters the environment of peripheral sensory nerves and reduces the local concentration of inflammatory mediators, leading to a functional attenuation of peripheral nerve excitability.


Sensory Interference via Counterirritation

A secondary, rapid-onset mechanism involves generating a distinct sensory input at the skin surface through counterirritation. This action bypasses the need for biochemical modulation and instead stimulates superficial cutaneous sensory nerves. This creates a competing, non-painful signal (such as warmth) that interferes with the transmission of deeper nociceptive signals to the central nervous system. This domain of action is applied when rapid, temporary adjustment of receptor activity is required to achieve a masking effect on the transmission of sensory input.

Dosage and Administration Information

How to Use Myofit (Mycophenolic Acid)

Myofit is an oral immunosuppressive medication used for the continuous prophylaxis of organ rejection in kidney transplant recipients. Its administration follows a highly standardized regimen.


Administration Route and Dosing

Myofit is administered exclusively by the oral route as delayed-release tablets, available in 180 mg and 360 mg strengths. For adult patients, the standard maintenance regimen involves taking 720 mg twice daily (every 12 hours), establishing a total daily dose of 1,440 mg. Treatment initiation is typically required within 48 hours following the kidney transplantation procedure. The medicine must always be used as part of a combination immunosuppressive therapy, alongside agents like corticosteroids.


Key Administration Conditions

A critical instruction is that the medicine must be taken on an empty stomach to ensure consistent absorption. This is defined as administration either one hour before or two hours after food intake. Furthermore, the delayed-release tablets must be swallowed whole. Patients are instructed never to crush, cut, or chew the tablets, as doing so compromises the integrity of the protective enteric coating required for proper delivery of the drug.


Population-Specific Usage Patterns

The dosing protocol includes specific rules for pediatric patients who are 5 years old, with the regimen calculated based on body surface area (400 mg/m^2 twice daily) up to the maximum adult dose. No dose adjustments are required for older adults or for patients who experience delayed renal graft function post-operatively. The drug is intended for continuous, long-term maintenance use.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence in Crohn’s Disease (CD)

Research explored the potential association between treatment and clinical outcomes in patients with active, moderately severe Crohn’s Disease (CD) who have not responded adequately to conventional therapy. The primary outcomes assessed in the studies were clinical response, clinical remission, and mucosal healing.

Research Area Key Evaluation Parameters
Clinical Response & Remission Proportion of participants achieving clinical response and clinical remission at weeks 4 and 8. Researchers recorded the proportion of participants in remission through week 54 in the long-term studies.
Mucosal Healing Endoscopic evaluation was used to assess whether mucosal healing occurred in participants. The rate of mucosal healing was examined as a key secondary outcome.

Mechanism of Action (MoA) and Immunogenicity

Research explored the interaction of the compound with TNF alpha as part of the investigation into the inflammatory response. Further research investigated the development of anti-drug antibodies (ADA) and assessed the relationship between ADA formation and study discontinuations. This immunogenic profile is routinely tracked in long-term safety evaluations.


Safety and Tolerability Profile

Safety studies examined the frequency of adverse events, including infections, infusion reactions, and the development of autoantibodies. The incidence of serious infections, including opportunistic infections, was monitored across all study phases. Studies noted that screening for active or latent tuberculosis and Hepatitis B was performed prior to starting therapy in the research setting. The long-term safety profile of the treatment was evaluated over a specific study duration.

Frequently Asked Questions (FAQ)

Common questions about Myofit (FAQ)

Q: What are the most commonly reported side effects of Myofit?

According to official product information, the most frequently reported reactions are classified as Very Common, meaning they may affect more than 1 in 10 patients. These often include effects on the blood, such as a low white blood cell count (leukopenia), and gastrointestinal effects like diarrhea, nausea, and vomiting. The medicine’s safety profile notes a potential for an increased incidence of serious infections.

Q: Can I take Myofit with over-the-counter cold medicines?

Regulatory documents include a caution regarding combining Myofit with other agents that have Central Nervous System (CNS) depressant activity. This category can include antihistamines, which are found in some over-the-counter cold medicines. Combining these substances may lead to potential issues like excessive sedation or impaired motor function, and their use together warrants close supervision by a healthcare provider.

Q: What is the pregnancy safety category for Myofit?

Official documentation strictly contraindicates the use of Myofit during pregnancy. This is due to a significant risk of embryo-fetal toxicity, which includes an increased risk of miscarriage and congenital malformations. The regulatory profile specifies that females of reproductive potential should use highly effective contraception.

Q: Is it common to have mild stomach upset after starting Myofit?

Diarrhea, nausea, vomiting, and abdominal pain are specifically listed in the official safety profile as Very Common side effects, meaning they may affect more than 1 in 10 patients. These gastrointestinal effects are among the most frequently reported reactions.

Q: Is Myofit similar to other drugs ending in '-ril'?

The active substance in Myofit is classified either as an immunosuppressive agent or a topical salicylate, depending on the formulation. It is not classified as an ACE inhibitor, which is the drug class typically represented by medicine names ending with the suffix '-pril'.

Q: Is Myofit a muscle relaxant?

Myofit is classified by regulatory authorities either as a Topical Analgesic preparation or as an Immunosuppressive Agent, depending on the use condition. Official documents do not define the drug as belonging to the muscle relaxant pharmacological class.

Q: Is Myofit a type of pain reliever?

The formulation of Myofit containing Triethanolamine Salicylate is defined as a Topical Analgesic preparation. Its general purpose, as recognized by the FDA, to provide temporary relief from localized pain in the affected area.

Q: How quickly should I expect Myofit to start working?

Official documents note that the topical formulation's action involving counterirritation provides a secondary, rapid-onset sensory effect. However, the regulatory documentation does not provide a general timeline for the onset of the main clinical benefit (such as for organ rejection prophylaxis).

Q: Does Myofit cause weight gain?

Weight gain is not listed in the official documents as a common adverse effect. Regulatory documents mention unexplained weight loss as a symptom that a healthcare provider should be informed about.

Q: Is it common to feel drowsy when taking Myofit?

The official label notes that the medication may affect your level of alertness and coordination. Because of this, people are advised against activities requiring mental sharpness, such as driving, until they know how the drug affects them. Dizziness is also listed as a symptom to report.

Q: What is the list of ingredients in Myofit?

The active ingredient in the prescription tablet formulation is Mycophenolic Acid. Official documentation also lists inactive ingredients, which include compounds such as lactose anhydrous, magnesium stearate, and titanium dioxide.

Q: What happens if I drink alcohol while taking Myofit?

Official warnings indicate that combining the medication with alcohol may contribute to an increase in certain side effects, such as dizziness and a greater negative impact on coordination.

Q: Why do doctors prescribe Myofit?

According to the official Indications and Usage, the medicine is prescribed to prevent organ rejection in people who have received a kidney transplant. It is typically used as part of a combination immunosuppressive therapy regimen.

Q: Can Myofit be used for conditions other than the main listed use?

The medicine's regulatory approval is strictly defined for the prevention of organ rejection in kidney transplant recipients. Regulatory documents define only the approved uses for the medication; information on other uses is not included in the official labeling.

Q: Are headaches a common side effect of Myofit?

Headache is listed in the official documents as a reported side effect of the medication.

Q: Can Myofit affect sleep patterns?

The official product safety profile indicates that trouble sleeping (insomnia) is listed as a reported side effect of the medication.

Q: Is Myofit known to interact with herbal supplements?

The regulatory labeling explicitly prohibits concomitant use with the herbal product St. John’s Wort due to the risk that it may reduce the drug's effectiveness. Official guidance on other herbal products may not be explicitly listed.

Q: Are there any reported interactions with popular supplements like Vitamin D or Magnesium?

Official labeling states that oral Magnesium supplements require specific timing constraints (separation by at least 2 hours) to prevent reduced absorption. Conversely, no interaction was found with Vitamin D3 (cholecalciferol) in regulatory documents.

Q: What kind of specialist usually prescribes Myofit?

Due to its primary use in preventing organ rejection in patients who have undergone a transplant, prescribing and ongoing patient management is typically handled by specialists in transplant medicine, such as transplant nephrologists or surgeons.

Q: Are there any long-term research studies on Myofit?

Official documents and post-marketing commitments indicate that the long-term safety and effectiveness of the drug are routinely tracked. This includes post-marketing surveillance studies conducted over several years to monitor long-term outcomes and safety.

Q: Can Myofit cause sensitivity to sunlight?

The medication is associated with a heightened risk of skin cancer. The label advises that exposure to sunlight and UV light should be limited by using protective clothing and a high-factor sunscreen, as the medicine is associated with a heightened risk of skin cancer.

Q: Is the Myofit tablet scored so it can be broken?

The official administration instructions require the delayed-release tablet to be swallowed whole to preserve the medicine's enteric coating. Official guidance states that crushing, breaking, or chewing is not permitted.

Q: What should I do if I notice a change in my heart rate while on Myofit?

Fast or abnormal heartbeat is listed as a symptom for which prompt attention by a healthcare provider may be warranted, as it may be associated with underlying blood disorders or other serious effects.

How should Myofit be stored and disposed of?

How to Store and Dispose of Myofit (Mycophenolic Acid)

Myofit (mycophenolic acid delayed-release tablets) must be stored strictly according to regulatory standards to maintain product stability and ensure safety.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 25 C (77 F), with permitted excursions to 15 C–30 C.
Protection The product must be protected from moisture and kept in its closed container.
Child Safety Must be kept out of the sight and reach of children.

Special Handling and Disposal

If the tablet is damaged, avoid inhalation or contact of the powder with skin or mucous membranes, as it is a hazardous medicinal product.

Unused or expired product should be disposed of via an authorized drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance and placed in a sealed bag before discarding with household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Myofit found in:

A-Z Index: